Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DAVITA INC.DVA · Entity 3482 | Director | August 15, 2026 | August 18, 2026 |
| LABCORP HOLDINGS INC.LH · Entity 1277 | Director · President & CEO | August 11, 2026 | August 12, 2026 |
| Merck & Co., Inc.MRK · Entity 2807 | EVP & Pres-Global Human Health | November 01, 2018 | November 02, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DAVITA INC.
Report date August 15, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,970 |
Reported balance
After 2026-08-15 transaction · row 1
1 source rowRow 1 · 2026-08-15 · Grant · Acquired 278 · Balance 5,970 |
LABCORP HOLDINGS INC.
Report date August 11, 2026 · Filed August 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 102,565 |
Reported balance
After 2026-08-11 transaction · row 1
1 source rowRow 1 · 2026-08-11 · Sale · Disposed 4,669 · Balance 102,565 F1: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
Merck & Co., Inc.
Report date November 01, 2018 · Filed November 02, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2018-11-01 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2018-11-01 · Exercise / conversion · Acquired 277,879 · Balance 277,879 Row 2 · 2018-11-01 · Sale · Disposed 132,744 · Balance 145,135 F1: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.6800 to $73.3900, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Row 3 · 2018-11-01 · Sale · Disposed 145,135 · Balance 0 F1: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.4000 to $74.0200, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.29 · Expires 2022-05-01 | Direct | 0 |
Reported balance
After 2018-11-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-11-01 · Exercise / conversion · Disposed 277,879 · Balance 0 F5: The option became exercisable in equal installments on 5/2/2013, 5/2/2014 and 5/2/2015. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 55,405.9747 |
Reported balance
Holding disclosure · report date 2018-11-01 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 55,405.9747 F4: Holdings include shares acquired in dividend reinvestment transactions. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.6800 to $73.3900, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.4000 to $74.0200, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
F4: Holdings include shares acquired in dividend reinvestment transactions.
F5: The option became exercisable in equal installments on 5/2/2013, 5/2/2014 and 5/2/2015.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 11, 2024 Filed Feb 13, 2024 17:17 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 2,964 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-004643 · form4.xml · derivative · entry 3 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,277 Underlying: Common Stock · 2,964 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 11, 2023. F3 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 11, 2023. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 11, 2024 Filed Feb 13, 2024 17:17 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 2,964 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-004643 · form4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,225 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 07, 2024 Filed Feb 8, 2024 20:27 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 3,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-003961 · form4.xml · derivative · entry 5 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,241 Underlying: Common Stock · 3,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F7 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 7, 2024. F7 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 7, 2024. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 07, 2024 Filed Feb 8, 2024 20:27 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Tax withholdingCommon Stock | 1,149 | $223.71 | $257,042.79 |
DisclosureSEC source: 0001127602-24-003961 · form4.xml · nonDerivative · entry 2 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,261 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 07, 2024 Filed Feb 8, 2024 20:27 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 3,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-003961 · form4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,410 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 20:27 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantNon-qualified Stock Options · Derivative | 41,400 | $0.00 Strike: $222.28 | $0.00 |
DisclosureSEC source: 0001127602-24-003961 · form4.xml · derivative · entry 4 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,400 Underlying: Common Stock · 41,400 shares Expires 2034-02-05 F5 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F6 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 20:27 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantRestricted Stock Unit · Derivative | 13,380 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-003961 · form4.xml · derivative · entry 3 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,491 Underlying: Common Stock · 13,380 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 6, 2025. F3 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 6, 2025. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 02, 2024 Filed Feb 6, 2024 20:58 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 3,094 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-003550 · form4.xml · derivative · entry 3 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,111 Underlying: Common Stock · 3,094 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units vested in three equal annual installments beginning on February 2, 2022 and are now fully vested. F3 · derivative.expiration_date: The Restricted Stock Units vested in three equal annual installments beginning on February 2, 2022 and are now fully vested. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Amount includes an additional 1,364 Restricted Stock Units resulting from the final adjustment ratio calculated pursuant to the terms of the Employee Matters Agreement by and between Laboratory Corporation of America Holdings and Fortrea Holdings Inc. Read SEC document |
| February 02, 2024 Filed Feb 6, 2024 20:58 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Tax withholdingCommon Stock | 822 | $221.54 | $182,105.88 |
DisclosureSEC source: 0001127602-24-003550 · form4.xml · nonDerivative · entry 2 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,160 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 02, 2024 Filed Feb 6, 2024 20:58 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 3,094 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-003550 · form4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,982 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| November 15, 2023 Filed Nov 17, 2023 22:44 UTC | DAVITA INC. DVA · Entity 3482 | GrantCommon Stock | 529 | $0.00 | $0.00 |
DisclosureSEC source: 0000927066-23-000221 · wk-form4_1700261046.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,259 Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 21:15 UTC | DAVITA INC. DVA · Entity 3482 | GrantCommon Stock | 475 | $0.00 | $0.00 |
DisclosureSEC source: 0000927066-23-000195 · wk-form4_1692306945.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,730 Read SEC document |
| June 30, 2023 Filed Jul 6, 2023 00:04 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantRestricted Stock Unit · Derivative | 73,013 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-020295 · form4.xml · derivative · entry 1 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,841 Underlying: Common Stock · 73,013 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: In connection with the spin-off ("Spin-Off") of Fortrea Holdings Inc. ("Fortrea") by Laboratory Corporation of America Holdings ("Labcorp"), performance awards granted by Labcorp in 2021 for the 3-year performance period through December 31, 2023 (the "2021 PSA") were converted into time-vesting restricted stock units ("RSUs") of Labcorp pursuant to the terms of the Employee Matters Agreement by and between Labcorp and Fortrea (the "EMA"). The 2021 PSA was converted into a number of time-vesting Labcorp RSUs based on the degree of achievement of the performance criteria subject to the 2021 PSA prior to the Spin-Off and the adjustment ratio that applies to Labcorp equity awards in the Spin-Off, with vesting on the 30th day following Labcorp's filing of an annual report on Form 10-K that includes audited financial statements with respect to the 3-year period ending December 31, 2023. Amounts are estimates pending finalization of the adjustment ratio pursuant to the EMA. F2 · derivative.expiration_date: In connection with the spin-off ("Spin-Off") of Fortrea Holdings Inc. ("Fortrea") by Laboratory Corporation of America Holdings ("Labcorp"), performance awards granted by Labcorp in 2021 for the 3-year performance period through December 31, 2023 (the "2021 PSA") were converted into time-vesting restricted stock units ("RSUs") of Labcorp pursuant to the terms of the Employee Matters Agreement by and between Labcorp and Fortrea (the "EMA"). The 2021 PSA was converted into a number of time-vesting Labcorp RSUs based on the degree of achievement of the performance criteria subject to the 2021 PSA prior to the Spin-Off and the adjustment ratio that applies to Labcorp equity awards in the Spin-Off, with vesting on the 30th day following Labcorp's filing of an annual report on Form 10-K that includes audited financial statements with respect to the 3-year period ending December 31, 2023. Amounts are estimates pending finalization of the adjustment ratio pursuant to the EMA. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| May 15, 2023 Filed May 17, 2023 21:42 UTC | DAVITA INC. DVA · Entity 3482 | GrantCommon Stock | 516 | $0.00 | $0.00 |
DisclosureSEC source: 0000927066-23-000143 · wk-form4_1684359747.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,255 Read SEC document |
| March 30, 2023 Filed Apr 3, 2023 14:14 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Tax withholdingCommon Stock | 18,646 | $224.70 | $4,189,756.20 |
DisclosureSEC source: 0001127602-23-011751 · form4.xml · nonDerivative · entry 2 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,888 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| March 30, 2023 Filed Apr 3, 2023 14:14 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantCommon Stock | 42,353 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-011751 · form4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,534 F1 · kind: Shares acquired on March 30, 2023, pursuant to a performance award granted on February 4, 2020, relating to performance during the three-year period ended December 31, 2022. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 21:42 UTC | DAVITA INC. DVA · Entity 3482 | GrantCommon Stock | 658 | $0.00 | $0.00 |
DisclosureSEC source: 0000927066-23-000059 · wf-form4_167908930727647.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 739 Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 19:55 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Tax withholdingCommon Stock | 1,170 | $248.13 | $290,312.10 |
DisclosureSEC source: 0001127602-23-005101 · form4.xml · nonDerivative · entry 2 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,181 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 19:55 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 2,656 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-005101 · form4.xml · derivative · entry 3 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,828 Underlying: Common Stock · 2,656 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 11, 2023. F3 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 11, 2023. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 19:55 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 2,656 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-005101 · form4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,351 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 07, 2023 Filed Feb 9, 2023 14:33 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantNon-qualified Stock Options · Derivative | 27,400 | $0.00 Strike: $247.24 | $0.00 |
DisclosureSEC source: 0001127602-23-004103 · form4.xml · derivative · entry 2 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,400 Underlying: Common Stock · 27,400 shares Expires 2033-02-06 F4 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F5 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 07, 2023 Filed Feb 9, 2023 14:33 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantRestricted Stock Unit · Derivative | 8,740 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-004103 · form4.xml · derivative · entry 1 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,484 Underlying: Common Stock · 8,740 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 7, 2024. F2 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 7, 2024. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 06, 2023 Filed Feb 7, 2023 19:55 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Tax withholdingCommon Stock | 1,368 | $244.50 | $334,476.00 |
DisclosureSEC source: 0001127602-23-003710 · form4.xml · nonDerivative · entry 2 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,695 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 04, 2023 Filed Feb 7, 2023 19:55 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 3,507 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-003710 · form4.xml · derivative · entry 3 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,744 Underlying: Common Stock · 3,507 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units vested in three equal annual installments beginning on February 4, 2021 and are now fully vested. F3 · derivative.expiration_date: The Restricted Stock Units vested in three equal annual installments beginning on February 4, 2021 and are now fully vested. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 04, 2023 Filed Feb 7, 2023 19:55 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 3,507 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-003710 · form4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 02, 2023 Filed Feb 6, 2023 20:49 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 2,773 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-003536 · form4.xml · derivative · entry 3 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,251 Underlying: Common Stock · 2,773 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 2, 2022. F3 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 2, 2022. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 02, 2023 Filed Feb 6, 2023 20:49 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Tax withholdingCommon Stock | 805 | $254.99 | $205,266.95 |
DisclosureSEC source: 0001127602-23-003536 · form4.xml · nonDerivative · entry 2 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,556 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 02, 2023 Filed Feb 6, 2023 20:49 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 2,773 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-003536 · form4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,361 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| November 15, 2022 Filed Nov 16, 2022 22:31 UTC | DAVITA INC. DVA · Entity 3482 | GrantCommon Stock | 81 | $0.00 | $0.00 |
DisclosureSEC source: 0000927066-22-000186 · wf-form4_166863786944927.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81 Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 21:01 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 2,007 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-024922 · form4.xml · derivative · entry 3 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,024 Underlying: Common Stock · 2,007 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units vested in three equal annual installments beginning on November 1, 2020 and are now fully vested. F3 · derivative.expiration_date: The Restricted Stock Units vested in three equal annual installments beginning on November 1, 2020 and are now fully vested. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 21:01 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Tax withholdingCommon Stock | 893 | $222.56 | $198,746.08 |
DisclosureSEC source: 0001127602-22-024922 · form4.xml · nonDerivative · entry 2 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,588 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 21:01 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 2,007 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-024922 · form4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,481 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 18:49 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantNon-qualified Stock Options · Derivative | 28,100 | $0.00 Strike: $276.26 | $0.00 |
DisclosureSEC source: 0001127602-22-004969 · form4.xml · derivative · entry 2 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,100 Underlying: Common Stock · 28,100 shares Expires 2032-02-10 F4 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F5 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 18:49 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantRestricted Stock Unit · Derivative | 7,970 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-004969 · form4.xml · derivative · entry 1 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,031 Underlying: Common Stock · 7,970 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 11, 2023. F2 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 11, 2023. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 04, 2022 Filed Feb 8, 2022 16:10 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 3,507 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-003648 · form4.xml · derivative · entry 3 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,061 Underlying: Common Stock · 3,507 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 4, 2021. F3 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 4, 2021. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 04, 2022 Filed Feb 8, 2022 16:10 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Tax withholdingCommon Stock | 1,412 | $277.48 | $391,801.76 |
DisclosureSEC source: 0001127602-22-003648 · form4.xml · nonDerivative · entry 2 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,474 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 04, 2022 Filed Feb 8, 2022 16:10 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 3,507 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-003648 · form4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,886 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 14:36 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 2,773 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-003275 · form4.xml · derivative · entry 3 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,568 Underlying: Common Stock · 2,773 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 2, 2022. F3 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 2, 2022. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 14:36 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Tax withholdingCommon Stock | 803 | $273.18 | $219,363.54 |
DisclosureSEC source: 0001127602-22-003275 · form4.xml · nonDerivative · entry 2 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,379 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 14:36 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 2,773 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-003275 · form4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,182 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 15:51 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 2,007 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-028239 · form4.xml · derivative · entry 3 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,341 Underlying: Common Stock · 2,007 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on November 1, 2020. F3 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on November 1, 2020. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 15:51 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Tax withholdingCommon Stock | 886 | $288.78 | $255,859.08 |
DisclosureSEC source: 0001127602-21-028239 · form4.xml · nonDerivative · entry 2 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,409 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 15:51 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 2,007 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-028239 · form4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,295 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 20:48 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 3,506 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-004353 · form4.xml · derivative · entry 3 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,348 Underlying: Common Stock · 3,506 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 4, 2021. F3 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 4, 2021. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 20:48 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Tax withholdingCommon Stock | 1,028 | $223.78 | $230,045.84 |
DisclosureSEC source: 0001127602-21-004353 · form4.xml · nonDerivative · entry 2 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,288 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 20:48 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 3,506 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-004353 · form4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,316 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 22:18 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantNon-qualified Stock Options · Derivative | 29,000 | $0.00 Strike: $233.39 | $0.00 |
DisclosureSEC source: 0001127602-21-004011 · form4.xml · derivative · entry 2 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,000 Underlying: Common Stock · 29,000 shares Expires 2031-02-01 F4 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F5 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 22:18 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantRestricted Stock Unit · Derivative | 8,320 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-004011 · form4.xml · derivative · entry 1 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,854 Underlying: Common Stock · 8,320 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 2, 2022. F2 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 2, 2022. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 22:43 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 2,006 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-028188 · form4.xml · derivative · entry 3 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,534 Underlying: Common Stock · 2,006 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on November 1, 2020. F3 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on November 1, 2020. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 22:43 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Tax withholdingCommon Stock | 885 | $207.23 | $183,398.55 |
DisclosureSEC source: 0001127602-20-028188 · form4.xml · nonDerivative · entry 2 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,810 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.